How NVIDIA Is Backing AI Innovation in Women's Health
6 min read
NVIDIA's expansion into healthcare AI has been one of the defining stories of the past two years — spanning drug discovery, surgical robotics, medical imaging, and clinical documentation. But a less-discussed dimension of that push is the company's deepening investment in a historically underserved area of health: women's health. Through a combination of startup acceleration via the NVIDIA Inception Programme, internal employee benefits, and its broader BioNeMo open AI platform for biomedical research, NVIDIA is positioning itself as a foundational enabler of the next generation of data-driven, personalised healthcare for women.
Hertility Joins NVIDIA Inception: Tackling the Gender Data Gap
The most direct expression of NVIDIA's women's health investment is the acceptance of Hertility into the NVIDIA Inception Programme — a milestone that positions the pioneering reproductive health platform alongside a global community of AI-driven companies dedicated to transforming healthcare. Hertility's core mission is to build the largest global dataset on female reproductive health, currently comprising more than 835,000 data variables collected from women across fertility, hormonal wellbeing, and reproductive health.
The gender data gap in medicine is well documented and consequential. For decades, women have been underrepresented in clinical research — leaving healthcare solutions often built on data that reflects male physiology and demographics. The result is diagnostic tools, treatment protocols, and medical standards that routinely underperform for women, particularly in areas as fundamental as hormonal health, fertility, endometriosis, and menopause. Hertility's proprietary dataset is designed to correct this imbalance at the foundation — building AI tools that genuinely reflect the diversity and complexity of female biology at population scale.
"This partnership marks an important step as we continue building toward a foundational AI platform for women's health, one designed to ensure that 51% of the world finally benefits from data-driven medicine. We're only just getting started."
— Dr Helen O'Neill, CEO and Founder, Hertility
The NVIDIA Inception Programme: Infrastructure for Serious AI Development
The NVIDIA Inception Programme is far more than a marketing badge. It provides accepted startups with access to NVIDIA's cutting-edge technology, AI expertise, and global investor network — the infrastructure required for serious AI product development at scale. For a company like Hertility, which is building AI-driven diagnostic tools that must process and learn from hundreds of thousands of data variables across diverse female populations, GPU infrastructure and AI engineering support are not optional extras — they are prerequisites.
The programme has now grown to encompass more than 5,000 healthcare and life sciences startups, with digital health leading at more than 2,000 members — a scale that reflects the depth of NVIDIA's commitment to accelerating AI-native healthcare innovation, not just large pharmaceutical incumbents. Through its Inception membership, Hertility aims to expand its AI capabilities, shorten diagnostic timelines, and improve patient outcomes by delivering real-time, personalised reproductive health solutions.
"If the world shifted to proactive reproductive and hormonal health screening, health systems could save over eight trillion in avoidable costs. Eight trillion, unlocked through earlier diagnosis, earlier intervention and less disease progression."
— Deirdre O'Neill, Co-Founder and Chief Commercial & Legal Officer, Hertility
"Building Your Family": NVIDIA's Internal Benefits Commitment
NVIDIA's women's health commitment extends inside the company as well. Through its "Building Your Family" initiative, NVIDIA offers its own employees a comprehensive suite of fertility, family formation, and reproductive health resources — covering adoption, fertility testing, IVF treatment, and surrogacy guidance. The programme includes:
- Inflection (formerly FertilityIQ) — Educational resources and expert access covering IVF, PCOS, and menopause, helping employees navigate complex reproductive health decisions.
- Peppy — Smartphone access to human experts providing personalised support for menopause, period pain, endometriosis, and PCOS — available to all who identify as women, including trans, non-binary, and gender-nonconforming individuals.
- WIN (Women's Infertility Network) — For employees with Cigna or Kaiser medical plans, providing 24/7 Nurse Care Managers, treatment guidance, emotional support, and surrogacy administration.
The programme reflects a recognition that technology companies' stated commitment to advancing women's health must also be demonstrated in how they support their own workforce — not just in the startups they invest in or the research they fund.
The Broader Platform: BioNeMo and the $1 Billion Eli Lilly Partnership
The Hertility partnership sits within a far larger strategic push in healthcare AI. At GTC 2026, NVIDIA announced significant expansions of BioNeMo — its open AI development platform for healthcare and life sciences — including new models for protein binder design (Proteina-Complexa), RNA structure prediction, molecular synthesis, and toxicity prediction. The platform is being used by Novo Nordisk, Viva Biotech, and Manifold Bio for therapeutic protein design, and has expanded the AlphaFold Protein Structure Database in collaboration with EMBL, Google DeepMind, and Seoul National University — calculating approximately 30 million new protein structures.
Underpinning the entire healthcare AI ambition is the landmark $1 billion, five-year partnership with Eli Lilly — announced at the J.P. Morgan Healthcare Conference in January 2026 — which includes a new AI co-innovation lab in the San Francisco Bay Area where scientists from both organisations will work together on accelerated drug discovery, clinical development optimisation, and advanced manufacturing applications. Roche has simultaneously deployed more than 3,500 NVIDIA Blackwell GPUs — the largest announced GPU footprint of any pharmaceutical company — to accelerate R&D, diagnostics, and manufacturing efficiencies.
Why Women's Health Is the Frontier That Matters
According to the World Economic Forum, women's health remains significantly underfunded relative to its importance for global wellbeing and economic growth. Yet the economic case for investing in preventive reproductive and hormonal health is overwhelming — as Hertility's own modelling shows, proactive reproductive and hormonal health screening could unlock trillions in avoided healthcare costs through earlier diagnosis and intervention.
By backing platforms like Hertility through Inception, expanding BioNeMo's capabilities for personalised medicine, and investing in employee family-formation benefits at scale, NVIDIA is making a multidimensional bet on women's health as one of the highest-impact opportunities in the next generation of AI-driven healthcare. The combination of compute infrastructure, open AI models, startup ecosystem investment, and internal benefit programmes represents a coherent and serious commitment — and one that is arriving at precisely the moment when the data and model capabilities needed to make personalised women's health a clinical reality are finally within reach.
Key Takeaways
- Hertility — building the world's largest female reproductive health dataset with 835,000+ data variables — has been accepted into the NVIDIA Inception Programme, targeting a foundational AI platform for women's health.
- The NVIDIA Inception Programme now covers 5,000+ healthcare and life sciences startups, with 2,000+ in digital health — providing GPU infrastructure, AI expertise, and investor network access.
- Hertility's Co-Founder estimates that proactive reproductive and hormonal health screening could unlock over $8 trillion in avoided healthcare costs globally through earlier diagnosis and intervention.
- NVIDIA's internal "Building Your Family" initiative provides employees with fertility, IVF, adoption, menopause, and PCOS support through Inflection, Peppy, and WIN partnerships.
- The broader NVIDIA healthcare AI investment includes a $1 billion Eli Lilly partnership, Roche's 3,500-GPU AI factory deployment, and BioNeMo expansions covering protein design, RNA structure prediction, and drug discovery at GTC 2026.